Accepted for/Published in: JMIR Research Protocols
Date Submitted: Dec 4, 2022
Date Accepted: May 24, 2023
Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study Protocol
ABSTRACT
Background:
Interstitial lung disease is a broad term encompassing diseases of different bacgrounds. Interstitial pneumonia with autoimmune features (IPAF) is a recent term, which implies presence of autoimmunity.
Objective:
To provide clinical, serological, functional and radiological characteristics of a sample of Polish IPAF population;compare this population with patients with idiopathic and autoimmunity-induced interstitial pneumonias; search for prognostic and diagnostic biomarkers of IPAF in serum and bronchoalveolar lavage fluid.
Methods:
A multi-center prospective interventional study planned to recruit 240 participants, divided into the study group (IPAF patients) and two control groups (idiopathic interstitial pneumonias and connective tissue disease-associated interstitial pneumonias). Biological fluid samples will be collected according to Polish Respiratory Society management guidelines and will be stored at -80°C for further tests. Prospective 5-year observation is planned to determine clinical stability of IPAF. The study will be carried out according to the Code of Ethics of the World Medical Association (Declaration of Helsinki).
Results:
Not applicable yet.
Conclusions:
This study will be a step towards better understanding of IPAF etiopathogenesis and outcomes. Clinical Trial: ClinicalTrials.gov Identifier: NCT03870828
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.